A phase 2 trial suggests that the novel SNRI ammoxetine may effectively treat major depressive disorder while avoiding some side effects common to other antidepressants.

Compared with sham therapy, 12 days of personalized treatment with high-definition transcranial direct current stimulation ...

As daylight diminishes people can feel their mood dimming. In fact millions of U.S. adults experience seasonal affective ...

Research on rare post-mortem brain tissue shows changes in gene activity, offering new insight into the biological basis of ...

The FDA has cleared an accelerated protocol for a transcranial magnetic stimulation system in the treatment of depression and ...

Skoltech scientists and their colleagues from other Russian medical research centers and mental health institutions have ...

HealthDay News — Psilocybin-assisted therapy (PAT) shows long-term safety and efficacy for treating symptoms of major depressive disorder (MDD), according to a study published in the Journal of ...

Imagine wading through severe depression for years, taking medication after medication, with no relief. Now, envision discovering that what you were facing was not major depression but bipolar ...

Huntington Beach, CA – Moment of Clarity has published a new educational resource on the role of Transcranial Magnetic ...

Researchers found that 8.3% of US adults had at least one major depressive episode. In adolescents, the rate was 20.1%, with 29.2% of female adolescents reporting a major depressive episode. Major ...

A new study involving the German Center fo Research (DZD) provides strong evidence that sugary drinks affect not only ...

The approval of medicines called second-generation antipsychotics has allowed major depressive disorder (MDD) and other conditions linked to it to be treated. A person with MDD is usually prescribed ...